This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Basal Insulin Plus GLP-1 RAs: Consider Therapeutic Synergies to Achieve T2DM Glycemic Goals

Basal Insulin Plus GLP-1 RAs: Consider Therapeutic Synergies to Achieve T2DM Glycemic Goals

Format

Expert Perspective

Time to Complete

1 hour

Released

March 15, 2017

Expires

March 15, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Sanofi US

Program Description

Treatment strategies for patients with type 2 diabetes mellitus (T2DM) focus on the importance of targeting multiple pathophysiologic abnormalities associated with the disease and the need to recommend agents that target multiple sites of action to advance therapy. Efforts also should be made to combine agents that have complementary and additive mechanisms of action, such as basal insulin plus a glucagon-like peptide-1 receptor agonist (GLP-1 RA). An established body of evidence has shown that the combination of insulin plus a GLP-1 RA may help patients achieve their target A1C goals, addresses both fasting and postprandial glucose, and minimizes adverse effects such as hypoglycemia, thereby promoting adherence. Recent research studies have also documented the benefits of these 2 injectable agents in a fixed-ratio-delivery injectable pen, providing greater convenience for patients.

Intended Audience

Diabetologists, endocrinologists, internists, family/general practitioners, nurse practitioners, physician assistants, certified diabetes educators, and other clinicians involved in the care of patients with diabetes

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Identify the advantages and limitations of GLP-1 RAs
  • Explain the advantages and limitations of basal insulin
  • Compare the clinically relevant characteristics of GLP-1 RAs
  • Assess the advantages and limitations of treating T2DM with a fixed-ratio combination of insulin plus a short-acting GLP-1 vs administering those agents as separate injections
  • Individualize T2DM management strategies to meet patients’ treatment goals with consideration for both fasting plasma glucose and postprandial glucose, to minimize adverse effects of treatment, and to promote adherence

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

Guillermo Umpierrez, MD
Professor of Medicine
Emory University
Section Head
Diabetes and Endocrinology
Grady Health System
Atlanta, Georgia

Dr. Umpierrez has received research grants from AstraZeneca, Merck & Co., Novo Nordisk, and Sanofi US and consulting fees from Sanofi US.

Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Tullis-Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Dr. Fonseca has received research grants from Abbott, Asahi Kasei Pharma America, Eli Lilly, GI Dynamics, Inc., Gilead Sciences, Inc., and Novo Nordisk. He has received consultant fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Nestlé Health Science - Pamlab, Inc., and Sanofi-Aventis.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of HME and Sanofi US. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cmequestions@haymarketmedical.com.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue


Related to this activity